The Dual‐Signal Model of Fungal Allergy: Pore‐Forming Toxins Prime Epithelial Breach to License Sequential Sensitization
Allergy · 2026-05 · 81 (5) · 1921-1923
DOI: 10.1111/all.70337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 09.04.2026. Verfasst von Peixin Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Meicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescent…. Die Arbeit nennt 6 Literaturangaben. Gefördert von: The Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Meicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child…
- Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Peixin Yang, Juan Li, Zhenghong Jiang, Heping Fang
Förderung
- The Noncommunicable Chronic Diseases-National Science and Technology Major Project
Zitieren
APA
Yang, P., Li, J., Jiang, Z., & Fang, H. (2026). The Dual‐Signal Model of Fungal Allergy: Pore‐Forming Toxins Prime Epithelial Breach to License Sequential Sensitization. Allergy, 81(5), 1921-1923. https://doi.org/10.1111/all.70337
Vancouver
Yang P, Li J, Jiang Z, Fang H. The Dual‐Signal Model of Fungal Allergy: Pore‐Forming Toxins Prime Epithelial Breach to License Sequential Sensitization. Allergy. 2026;81(5):1921-1923. doi:10.1111/all.70337
BibTeX
@article{Yang2026,
author = {Yang, Peixin and Li, Juan and Jiang, Zhenghong and Fang, Heping},
title = {The Dual‐Signal Model of Fungal Allergy: Pore‐Forming Toxins Prime Epithelial Breach to License Sequential Sensitization},
journal = {Allergy},
year = {2026},
volume = {81},
number = {5},
pages = {1921--1923},
doi = {10.1111/all.70337}
}
EUVIMED